> 数据图表谁能回答1.3 港股医药行业2026上半年业绩总览——创新药及制剂2026-9-51.3 港股医药行业2026上半年业绩总览——创新药及制剂部分创新药及制剂企业26H1财务数据（亿元）数据来源：ifind，西南证券整理；*按26H1收入规模排序，市值截至2026/09/0719代码公司2024H1收入2025H1瑞博生物海西新药亚盛医药-B复旦张江迈威生物-B康诺亚-B东瑞制药迈博药业-B华领医药-B德琪医药-B海王英特龙7.61061.HK 亿胜生物科技0.52162.HK5.82348.HK0.66996.HK5.48329.HK3.98049.HK 吉林长龙药业1.71477.HK 欧康维视生物-B0.76938.HK1.12181.HK1.02552.HK4.11349.HK1.22493.HK0.02637.HK8.26855.HK1.79966.HK 康宁杰瑞制药-B0690.HK 联康生物科技集团 2.610.09606.HK2.52616.HK2126.HK0.90.37630.HK0.09637.HK5.02256.HK2591.HK0.00.22575.HK0.12171.HK9939.HK0.00.02595.HK9887.HK0.0银诺医药-B轩竹生物-B科济药业-B开拓药业-B基石药业-B药明巨诺-B英派药业-B礼邦医药-B劲方医药维立志博-B映恩生物和誉-B8.05.06.30.55.04.42.91.02.72.23.91.03.02.33.22.812.30.51.10.30.16.10.60.20.50.10.90.02026H12025H16.86.25.55.14.44.44.24.24.03.83.73.13.13.02.72.42.22.11.11.11.01.00.80.70.60.50.40.45.8%812.1%9.2%-12.5%-8.9%11.6%75.4%56.6%152.7%111.8%-4.4%-12.4%0.0%-71.6%84.0%13.4%22.9%-80.5%22.5%-24.8%515.1%23.1%0.0%11.6%703.8%0.0%0.0%-4.2%2026H1-10.5%23.7%-13.4%864.8%-12.0%-0.9%44.1%304.3%45.1%74.3%-4.6%209.1%3.8%29.3%-15.1%-11.7%-82.2%314.8%4.7%316.8%760.0%-84.1%38.6%288.1%21.5%769.7%-52.1%543.6%1.5-3.44.9-1.70.41.0-1.5-1.4-1.0-1.40.7-4.40.01.6-0.40.6-2.90.2-2.4-1.2-1.62.1-0.8-1.1-3.5-0.7-4.5-1.81.5-0.81.0-0.80.21.0-1.3-0.90.011.80.1-5.51.1-5.90.20.7-20.7-2.7-2.7-1.3-2.13.3-1.2-1.1-0.8-0.8-7.0-1.71.012.21.22.20.11.2-1.00.20.3-0.30.4-5.20.8-8.2-0.40.3-9.2-2.5-0.5-0.9-1.6-1.9-1.2-0.8-0.7-0.8-2.2-2.23.8%76.6%-78.8%54.3%-49.7%-1.2%12.6%35.9%103.0%932.4%-91.9%-23.9%0.0%-462.4%148.1%12.7%-606.7%-1821.0%-11.2%-4.7%-27.6%58.8%-62.7%0.1%78.6%-16.5%-55.5%7.8%收入增速归母净利润2024H12025H12026H1归母净利润增速2025H1板块2026H1-35.7% 化学制剂1644.1%创新药创新药化学制剂18.0%383.3%-63.1% 化学制剂19.3%化学制剂25.2%123.0%982.1%-102.6% 化学制剂545.6% 化学制剂创新药创新药创新药5.4%创新药-24.8% 化学制剂-38.2%-287.5%-61.0%55.8%6.6%81.1%29.5%22.1%创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药创新药-158.9%5.7%32.1%11.5%9.0%68.5%-33.4%总市值(亿元)1120213211113884162263117136108723142847358155144468893107西南证券健康医疗
